Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

Congress is calling on 23andMe, the popular DNA-testing company, to answer questions regarding data privacy concerns ahead of its upcoming sale.

Lawmakers are seeking clarification on how 23andMe plans to protect the sensitive genetic information of its customers in the event of a sale to a new owner.

Privacy advocates have raised alarms about the potential misuse of genetic data, including concerns about insurance discrimination, data breaches, and law enforcement access.

The company has faced criticism in the past for its handling of user data, including sharing genetic information with third-party pharmaceutical companies.

Congress is demanding transparency from 23andMe and urging the company to prioritize the protection of user privacy in any future business dealings.

Lawmakers are also considering legislative action to regulate the collection and use of genetic data by companies like 23andMe.

Several members of Congress have expressed concerns about the lack of federal oversight in the growing field of genetic testing and personalized medicine.

Privacy advocates are calling for stronger regulations to protect consumer privacy and ensure that genetic data is not exploited for profit without consent.

As the sale of 23andMe looms, lawmakers are pushing for answers to address these critical privacy issues and safeguard the rights of consumers.